

P = 0.52
LV End-Systolic Volume (ml)
P = 0.53
LV End-Diastolic Volume (ml)
P = 0.83
LV Ejection Fraction (%)
P = 0.99
LV Infarct Volume (g)
Placebo (n=15)
remestemcel-L (n=10)

Figure 1




P = 0.17
P = 0.62
P = 0.07
P = 0.19
Placebo (n=15)
remestemcel-L (n=10)
LV End-Systolic Volume (ml)
LV End-Diastolic Volume (ml)
LV Ejection Fraction (%)
LV Infarct Volume (g)

Figure 2



The remestemcel-L group had >2 fold higher rate of LVESV treatment responders at 6 months post index AMI than the placebo group (p=0.095).

Figure 3



LVESV Change at 6 Month with Patients Baseline LVESV >70
(mL)
60
50
40
30
20
10
0
-10
-20
-30
-40
N=11
21.56
p-value=0.054
Control
N=14
-7.14
150M

Figure 4



LVESV change at 6 month for Patients baseline >80
p-value=0.035
25.7
Control
N=8
-7.14
150M
N=14
80
60
40
20
0
-20
-40
(mL)

Figure 5



LVESV change at 6 Month with baseline LVESF >90
p-value=0.035
25.75
Control
N=3
N=13
-8.31
150M
80.00
60.00
40.00
20.00
0.00
-20.00
-40.00
-60.00
(mL)

Figure 6



LVESV change at 6 Month with baseline LVESF >100
100
80
60
40
20
0
-20
-40
-60
46
p-value=0,022
Controi
N=7
N=11
-150 M
-8,09

Figure 7



LVESV Change at 6 Month with Baseline LVESV >110
(mL)
100
80
60
40
20
0
-20
-40
46
p-value=0.006
N=6
150 M
-13.17
Control
N=4

Figure 8



LVESV Change at 6 Month with baseline LVESV >120
100.00
80.00
60.00
40.00
20.00
0.00
-20.00
-40.00
(mL)
49.00
p-value=0.016
n=5
n=3
Control
150 M
-16.3

Figure 9